Talaris Therapeutics Inc.

Plus: Follow-ons for Sagimet, Tourmaline and Adicet, and PIPEs for Kura, ORIC and CalciMedica

Half of the U.S.-listed biotechs that announced reverse mergers this year had been public for four years or less

Plus: Tourmaline reverse-merging with Talaris, CAR T shows early efficacy in myasthenia gravis, and updates from AltPep, Solve and Intercept

Plus: Fenton succeeds CEO Requadt at Talaris, and an update from Sera

Plus: August PDUFA for Iveric’s GA therapy and updates from ALS Association, Avilar, Talaris, Senate’s HELP 

Plus: AbbVie gains LPAR1 antibody via $255M buy of DJS and updates for Denali, the U.K., Kite-Refuge, Takeda-Zedira, Immunic, Talaris, Celeris

Deal reflects firm’s move toward investing in growing biotechs with innovative programs

Entering a market for newly listed biotechs that has given some of its peers a lukewarm reception this quarter, Medicxi-backed Centessa rose modestly in its first trading day, falling short of a

Brandicourt, Ishrak, Nader, Popovits bring expertise across fields

With a postponement, a withdrawal and weakening aftermarket performance of NASDAQ IPOs, signs have begun to appear that investors’ long-robust appetite for new biotech listings has begun to